1,5,6-Trimethyl-benzotriazol | 25877-64-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1,5,6-Trimethyl-benzotriazol
• 英文别名: 1,5,6-Trimethylbenzotriazole
• CAS: 25877-64-9
• 化学式: C₉H₁₁N₃
• 分子量: 161.206
• InChiKey: TVRHYUZNPOOAEC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,5,6-Trimethyl-benzotriazol 在 potassium permanganate 作用下， 生成 1-methyl-1H-[1,2,3]triazole-4,5-dicarboxylic acid
  参考文献：
  名称：

  The Preparation of 1,5,6-Trimethylbenzotriazole and 1-Methyl-V-triazole-4,5-dicarboxylic Acid

  摘要：

  DOI：

  10.1021/ja01651a065
• 作为产物：
  描述：

  4，5-二甲基-1，2-苯二胺 在 sodium hydroxide 、 溶剂黄146 、 sodium nitrite 作用下， 生成 1,5,6-Trimethyl-benzotriazol
  参考文献：
  名称：

  The Preparation of 1,5,6-Trimethylbenzotriazole and 1-Methyl-V-triazole-4,5-dicarboxylic Acid

  摘要：

  DOI：

  10.1021/ja01651a065

文献信息

• TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080038225A1

  公开（公告）日：2008-02-14

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及以下式I或II的化合物，或其药用盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，同时也可作为抗病毒剂使用。本发明还涉及包含上述化合物的药物组合物，用于治疗HCV感染的患者。该发明还涉及通过向患者施用包含本发明化合物的药物组合物来治疗患者的HCV感染的方法。
• Reactions of chloride salts of 7-amino-9-ethylguanine and 1-amino-3-methylbenzimidazoles with lead(IV) acetate: Formation of 8-aza-9-ethylguanine and 1-methyl-1H-benzotriazoles
  作者：Toyo Kaiya、Shinsuke Aoyama、Kohfuku Kohda

  DOI：10.1016/s0960-894x(99)00123-7

  日期：1999.4

  Reaction of 7-amino-9-ethylguaninium chloride with lead(IV) acetate (LTA) in MeOH yielded 8-aza-9-ethylguanine. Similarly, the reaction of 1-amino-3-methylbenzimidazolium chloride or its substituted derivatives (6-methyl, 5,6-dimethyl and 5-nitro) with LTA gave the corresponding 1-methyl-1H-benzotriazole (or 1-methyl-2-azabenzimidazole) derivatives along with N-methylformananilide derivatives.

  氯化7-氨基-9-乙基鸟嘌呤与乙酸铅（IV）（MeOH）在MeOH中的反应生成8-氮杂-9-乙基鸟嘌呤。同样，1-氨基-3-甲基苯并咪唑氯化物或其取代的衍生物（6-甲基，5,6-二甲基和5-硝基）与LTA反应，得到相应的1-甲基-1H-苯并三唑（或1-甲基- 2-氮杂苯并咪唑衍生物）和N-甲基甲酰苯胺衍生物。
• TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20090047248A1

  公开（公告）日：2009-02-19

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及公式I或II的化合物，或其药学上可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制剂，用于治疗患有HCV感染的受试者。本发明还涉及通过向受试者给予本发明化合物的制剂来治疗受试者的HCV感染的方法。
• NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP3279997A1

  公开（公告）日：2018-02-07

  The purpose of the present invention is to provide a nonaqueous electrolyte that contains acetonitrile having an excellent balance between viscosity and the dielectric constant and a fluorine-containing inorganic lithium salt, wherein the generation of complex cations comprising a transition metal and acetonitrile is suppressed, excellent load characteristics are exhibited, and increases in internal resistance upon repeated charge/discharge cycles are suppressed; a further purpose of the present invention is to provide a nonaqueous secondary battery. The present invention relates to a nonaqueous electrolyte which contains: a nonaqueous solvent comprising acetonitrile; a fluorine-containing inorganic lithium salt; and a specific nitrogenous cyclic compound typified by benzotriazole.

  本发明的目的是提供一种非水电解液，该电解液含有在粘度和介电常数之间具有极佳平衡的乙腈和含氟无机锂盐，其中包含过渡金属和乙腈的复合阳离子的生成受到抑制，显示出极佳的负载特性，并且在重复充放电循环中内阻的增加受到抑制；本发明的另一个目的是提供一种非水二次电池。本发明涉及一种非水电解液，其中包含：由乙腈组成的非水溶剂；含氟无机锂盐；以及以苯并三唑为典型代表的特定含氮环状化合物。
• Nonaqueous electrolyte and nonaqueous secondary battery
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：US10756394B2

  公开（公告）日：2020-08-25

  The purpose of the present invention is to provide a nonaqueous electrolyte that contains acetonitrile having an excellent balance between viscosity and the dielectric constant and a fluorine-containing inorganic lithium salt, wherein the generation of complex cations comprising a transition metal and acetonitrile is suppressed, excellent load characteristics are exhibited, and increases in internal resistance upon repeated charge/discharge cycles are suppressed; a further purpose of the present invention is to provide a nonaqueous secondary battery. The present invention relates to a nonaqueous electrolyte which contains: a nonaqueous solvent comprising acetonitrile; a fluorine-containing inorganic lithium salt; and a specific nitrogenous cyclic compound typified by benzotriazole.

  本发明的目的是提供一种非水电解液，该电解液含有在粘度和介电常数之间具有极佳平衡的乙腈和含氟无机锂盐，其中包含过渡金属和乙腈的复合阳离子的生成受到抑制，显示出极佳的负载特性，并且在重复充放电循环中内阻的增加受到抑制；本发明的另一个目的是提供一种非水二次电池。本发明涉及一种非水电解液，其中包含：由乙腈组成的非水溶剂；含氟无机锂盐；以及以苯并三唑为典型代表的特定含氮环状化合物。